Volume 13, Issue 1 (Winter 2024)
aumj 2024, 13(1): 26-33 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azimi-Alamouty M, Habibi , M, Ebrahimi A, Jamalpoor Z. Investigating the effect of amniotic membrane solution on the behavior of human umbilical cord mesenchymal stem cells in an in vitro condition. aumj 2024; 13 (1) :26-33
URL: http://aums.abzums.ac.ir/article-1-1610-en.html
URL: http://aums.abzums.ac.ir/article-1-1610-en.html
1- Trauma Research Center, Aja University of Medical Sciences, Tehran, Iran
2- Iranian tissue bank and research center, Gene, Cell and Tissue Institute, Tehran University of medical sciences
3- Department of Tissue Engineering, School of Advanced Technologies in Medicine, Royan Institute, Tehran, Iran
4- Cytotech and Bioinformatics Research Group, Tehran, Iran
2- Iranian tissue bank and research center, Gene, Cell and Tissue Institute, Tehran University of medical sciences
3- Department of Tissue Engineering, School of Advanced Technologies in Medicine, Royan Institute, Tehran, Iran
4- Cytotech and Bioinformatics Research Group, Tehran, Iran
Abstract: (661 Views)
Introduction and objectives: Mesenchymal stem cells are a promising approach for the regeneration of damaged tissues. Engineered scaffolds loaded with cells is one of the methods of cell transplantation at the site of injury. However, viability of the cells loaded in the scaffold is still a challenge. Growth factors have a proven role in increasing the metabolic activity of cells. Amniotic membrane solution is a rich source of growth factor. The aim of this study was to determine the optimal concentration of amniotic membrane solution on the behavior of mesenchymal stem cells in in vitro.
Methods: Amniotic membrane solution was prepared by enzymatic method in predetermined concentrations. Mesenchymal stem cells loaded in hydrogel were treated with different concentrations. The viability, proliferation, and metabolic activity of the cells were evaluated.
Results: Cytotoxicity of amniotic membrane solution was measured by MTT method. Increasing the concentration from 0.1 to 1 mg/ml did not show any toxicity, and at the concentration of 1.5 mg/ml, a decrease in optical density (OD=0.58±0.012) was observed compared to the control (OD=0.39±0.014). The metabolic activity of the cell loaded in the hydrogel at a concentration of 1 mg/ml had a significant increase compared to the control group ( p 0.012) and the amount of DNA content in this group (19.6 ± 0.9 ng/matrix) confirmed it.
Conclusion: It is suggested that amniotic membrane solution as a rich source of growth factor with an optimal dose of 1mg/ml increases the viability and metabolic activity of the MSCs-loaded scaffold for cell therapy.
Methods: Amniotic membrane solution was prepared by enzymatic method in predetermined concentrations. Mesenchymal stem cells loaded in hydrogel were treated with different concentrations. The viability, proliferation, and metabolic activity of the cells were evaluated.
Results: Cytotoxicity of amniotic membrane solution was measured by MTT method. Increasing the concentration from 0.1 to 1 mg/ml did not show any toxicity, and at the concentration of 1.5 mg/ml, a decrease in optical density (OD=0.58±0.012) was observed compared to the control (OD=0.39±0.014). The metabolic activity of the cell loaded in the hydrogel at a concentration of 1 mg/ml had a significant increase compared to the control group ( p 0.012) and the amount of DNA content in this group (19.6 ± 0.9 ng/matrix) confirmed it.
Conclusion: It is suggested that amniotic membrane solution as a rich source of growth factor with an optimal dose of 1mg/ml increases the viability and metabolic activity of the MSCs-loaded scaffold for cell therapy.
Type of Study: Original |
Subject:
Special
Received: 2022/09/30 | Accepted: 2022/12/14 | Published: 2024/02/29
Received: 2022/09/30 | Accepted: 2022/12/14 | Published: 2024/02/29
References
1. Monsel, Antoine, et al. "Cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal stem cells." Anesthesiology 2014; 121.5: 1099-1121. [DOI:10.1097/ALN.0000000000000446]
2. Fan, X.L.; Zhang, Y.; Li, X.; Fu, Q.L. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell. Mol. Life Sci. 2020. 0.1007/s00018-020-03454-6
3. Kolios, G.; Moodley, Y. Introduction to stem cells and regenerative medicine. Respiration 2013; 85: 3-10. [DOI:10.1159/000345615]
4. Sumer, H.; Liu, J.; Roh, S. Mesenchymal Stem Cells and Regenerative Medicine. Stem Cells Int. 2018; 9810972. [DOI:10.1155/2018/9810972]
5. Tao, Y.C.; Wang, M.L.; Chen, E.Q.; Tang, H. Stem Cells Transplantation in the Treatment of Patients with Liver Failure. Curr. StemCell Res. Ther. 2018; 13: 193-201. [DOI:10.2174/1574888X13666180105123915]
6. Lee, J.H.; Park, H.J.; Kim, Y.A.; Lee, D.H.; Noh, J.K.; Kwon, C.H.; Jung, S.M.; Lee, S.K. Differentiation and major histocompatibility complex antigen expression in human liver-derived stem cells. Transplant. Proc. 2012; 44: 1113-1115. [DOI:10.1016/j.transproceed.2012.03.008]
7. Watt SM, Gullo F, van der Garde M, Markeson D, Camicia R, Khoo CP, Zwaginga JJ . The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential. Brit Med Bull 2013;108(1):25-53. [DOI:10.1093/bmb/ldt031]
8. Wang, Y.; Tian, M.;Wang, F.; Heng, B.C.; Zhou, J.; Cai, Z.; Liu, H. Understanding the Immunological Mechanisms of Mesenchymal Stem Cells in Allogeneic Transplantation: From the Aspect of Major Histocompatibility Complex Class I. Stem Cells Dev. 2019; 28:1141-1150. [DOI:10.1089/scd.2018.0256]
9. Correia CR, Reis RL, Mano JF. Design Principles and multifunctionality in cell encapsulation systems for tissue regeneration. Adv. Healthcare Mater. 2018; 7: 1701444.. [DOI:10.1002/adhm.201701444]
10. Costa RR, Mano JF. Polyelectrolyte multilayered assemblies in biomedical technologies. Chem Soc Rev. 2014; 43: 3453-3479. 10.1039/c3cs60393h. [DOI:10.1039/c3cs60393h]
11. Correia, Clara R., Maryam Ghasemzadeh-Hasankolaei, and João F. Mano. "Cell encapsulation in liquified compartments: Protocol optimization and challenges." Plos one 2019;14.6: e0218045. [DOI:10.1371/journal.pone.0218045]
12. Jeon, Oju, David W. Wolfson, and Eben Alsberg. "In‐situ formation of growth‐factor‐loaded coacervate microparticle‐embedded hydrogels for directing encapsulated stem cell fate." Advanced materials 2015;27.13: 2216-2223. [DOI:10.1002/adma.201405337]
13. Elkhenany, H., El-Derby, A., Abd Elkodous, M., Salah, R. A., Lotfy, A., & El-Badri, N. Applications of the amniotic membrane in tissue engineering and regeneration: the hundred-year challenge. Stem Cell Research and Therapy 2022;13( 1). [DOI:10.1186/s13287-021-02684-0]
14. John, T. Human amniotic membrane transplantation: Past, present, and future. In Ophthalmology Clinics of North America 2003 ; 16( 1): 43-65. [DOI:10.1016/S0896-1549(02)00110-4]
15. Investigation on the safety of amniotic membrane extracts in improving diabetic foot ulcers (phase 1 clinical trial study). Iranian Journal of Diabetes and Metabolism 2019.
16. Murphy, S. V., Skardal, A., Song, L., Sutton, K., Haug, R., Mack, D. L., Jackson, J., Soker, S., & Atala, A. Solubilized Amnion Membrane Hyaluronic Acid Hydrogel Accelerates Full-Thickness Wound Healing. Stem Cells Translational Medicine 2017; 6(11): 2020-2032. [DOI:10.1002/sctm.17-0053]
17. Li T, Xia M, Gao Y, Chen Y, Xu Y. Human umbilical cord mesenchymal stem cells: An overview of their potential in cell-based therapy. Expert Opin Biol Ther. 2015;15:1293-1306. [DOI:10.1517/14712598.2015.1051528]
18. Lu L, Zhao Q, Wang X, Xu Z, Lu Y, Chen Z, Liu Y. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006;91:1017.
19. Zhao, Xin, et al. "Photocrosslinkable gelatin hydrogel for epidermal tissue engineering." Advanced healthcare materials 2016;5.1:108-118. [DOI:10.1002/adhm.201500005]
20. Bank, H. L. "Assessment of islet cell viability using fluorescent dyes." Diabetologia 1987;30.10: 812-816. [DOI:10.1007/BF00275748]
21. Adan, Aysun, Yagmur Kiraz, and Yusuf Baran. "Cell proliferation and cytotoxicity assays." Current pharmaceutical biotechnology 2016;17.14: 1213-1221. [DOI:10.2174/1389201017666160808160513]
22. Cooper, D.M., Yu, E.Z., Hennessey, P., Ko, F. and Robson, M.C. Determination of Endogenous Cytokines in Chronic Wounds. Annals of Surgery 1994;219: 688-691. [DOI:10.1097/00000658-199406000-00012]
23. Ren, Xiaochen, et al. "Growth factor engineering strategies for regenerative medicine applications." Frontiers in bioengineering and biotechnology 2020;7: 469. [DOI:10.3389/fbioe.2019.00469]
24. Aguilar, Lilith M. Caballero, Saimon M. Silva, and Simon E. Moulton. "Growth factor delivery: Defining the next generation platforms for tissue engineering." Journal of controlled Release 2019;306: 40-58. [DOI:10.1016/j.jconrel.2019.05.028]
25. Thönes, Stephan, et al. "Hyaluronan/collagen hydrogels containing sulfated hyaluronan improve wound healing by sustained release of heparin-binding EGF-like growth factor." Acta biomaterialia 2019;86: 135-147. [DOI:10.1016/j.actbio.2019.01.029]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
